Condition
Hypophosphatemic Rickets
Total Trials
6
Recruiting
0
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Completed3
Active Not Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03651505Active Not Recruiting
X-linked Hypophosphatemia Disease Monitoring Program
NCT03748966Early Phase 1Active Not Recruiting
Calcitriol Monotherapy for X-Linked Hypophosphatemia
NCT04184661CompletedPrimary
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
NCT03581591Phase 3Completed
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
NCT03348644Not ApplicableCompletedPrimary
Milk Products in the Treatment of Hypophosphatemic Rickets
NCT00473187Phase 1UnknownPrimary
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
Showing all 6 trials